The divide between Eli Lilly and Novo Nordisk is widening after their latest earnings - CNBC
The divide between Eli Lilly and Novo Nordisk is widening after their latest earnings CNBC
Eli Lilly Company News
Lilly reports second-quarter 2026 financial results, raises full-year guidance, and highlights continued growth and pipeline progress - Eli Lilly and Company
Lilly reports second-quarter 2026 financial results, raises full-year guidance, and highlights continued growth and pipeline progress Eli Lilly and Company
Eli Lilly Surpasses Wall Street Estimates on Injectable GLP-1 Drugs - Pharmaceutical Executive
Eli Lilly Surpasses Wall Street Estimates on Injectable GLP-1 Drugs Pharmaceutical Executive
Lilly beats estimates on resilient demand for injectable GLP-1 drugs, widens gap with Novo - Reuters
Lilly beats estimates on resilient demand for injectable GLP-1 drugs, widens gap with Novo Reuters
Lilly Expands Retatrutide Access Amid Doctor Pushback - The American Journal of Managed Care
Lilly Expands Retatrutide Access Amid Doctor Pushback The American Journal of Managed Care
Eli Lilly Q2'26: Retatrutide heads toward filing amid BLA dispute - AllSci
Eli Lilly Q2'26: Retatrutide heads toward filing amid BLA dispute AllSci
Lilly Boosts Sales Guidance on Strong Demand for Obesity Drugs - Bloomberg
Lilly Boosts Sales Guidance on Strong Demand for Obesity Drugs Bloomberg
CVS Health enhances its direct-to-consumer weight management offerings - CVS Health
CVS Health enhances its direct-to-consumer weight management offerings CVS Health
Eli Lilly and Company Q2 2026 Earnings Call Summary - Yahoo Finance
Eli Lilly and Company Q2 2026 Earnings Call Summary Yahoo Finance
Eli Lilly (LLY) Stock Trades Up, Here Is Why - StockStory
Eli Lilly (LLY) Stock Trades Up, Here Is Why StockStory
Eli Lilly buys Goochland property for $38.3M - Virginia Business
Eli Lilly buys Goochland property for $38.3M Virginia Business
Novo Nordisk sues Eli Lilly over GLP-1 advertising, expanding scrutiny of drug marketing - Telehealth.org
Novo Nordisk sues Eli Lilly over GLP-1 advertising, expanding scrutiny of drug marketing Telehealth.org
Eli Lilly stock jumps after Q2 beat driven by GLP-1s (LLY:NYSE) - Seeking Alpha
Eli Lilly stock jumps after Q2 beat driven by GLP-1s (LLY:NYSE) Seeking Alpha
Eli Lilly will offer experimental obesity drug early to some patients. Who qualifies? - Houston Chronicle
Eli Lilly will offer experimental obesity drug early to some patients. Who qualifies? Houston Chronicle
Eli Lilly raises annual revenue forecast as GLP-1 drugs fuel growth - BNN Bloomberg
Eli Lilly raises annual revenue forecast as GLP-1 drugs fuel growth BNN Bloomberg
FDA Grants Breakthrough Therapy Status to Eli Lilly's Pancreatic Cancer Treatment - Investing News Network
FDA Grants Breakthrough Therapy Status to Eli Lilly's Pancreatic Cancer Treatment Investing News Network
Eli Lilly shares rise on revenue beat, raised outlook - Proactive financial news
Eli Lilly shares rise on revenue beat, raised outlook Proactive financial news
Eli Lilly to offer early access to next-gen obesity drug to some patients - Reuters
Eli Lilly to offer early access to next-gen obesity drug to some patients Reuters
Eli Lilly Ripe for Stock Split After Obesity Drug-Fueled Rally - Bloomberg
Eli Lilly Ripe for Stock Split After Obesity Drug-Fueled Rally Bloomberg
Lilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials, delivering significant improvements in weight and A1C - Eli Lilly and Company
Lilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials, delivering significant improvements in weight and A1C Eli Lilly and Company
Eli Lilly & Company price rises in volatile session - Forecast today - 06-08-2026 - Economies.com
Eli Lilly & Company price rises in volatile session - Forecast today - 06-08-2026 Economies.com
Lilly's Foundayo (orforglipron), the only oral GLP-1 taken without food or water restrictions, was associated with significant weight loss in women at every stage of menopause - Eli Lilly and Company
Lilly's Foundayo (orforglipron), the only oral GLP-1 taken without food or water restrictions, was associated with significant weight loss in women at every stage of menopause Eli Lilly and Company
Lilly to acquire AtaiBeckley to advance therapies for treatment-resistant depression and other mental health conditions - Eli Lilly and Company
Lilly to acquire AtaiBeckley to advance therapies for treatment-resistant depression and other mental health conditions Eli Lilly and Company
Novo Nordisk sues Eli Lilly, alleging the company's GLP-1 ads are 'deliberately false' - Scripps News
Novo Nordisk sues Eli Lilly, alleging the company's GLP-1 ads are 'deliberately false' Scripps News
Nasdaq Falls Over 100 Points; Eli Lilly Shares Gain On Upbeat Earnings - Benzinga
Nasdaq Falls Over 100 Points; Eli Lilly Shares Gain On Upbeat Earnings Benzinga
Novo Nordisk sues Eli Lilly over GLP-1 drug ads it calls ‘deceptive’ - STAT
Novo Nordisk sues Eli Lilly over GLP-1 drug ads it calls ‘deceptive’ STAT
Lilly announces three acquisitions to build infectious disease portfolio - Eli Lilly and Company
Lilly announces three acquisitions to build infectious disease portfolio Eli Lilly and Company
Lilly's triple agonist, retatrutide, demonstrated significant reductions in A1C and weight in first Phase 3 trial for treatment of type 2 diabetes - Eli Lilly and Company
Lilly's triple agonist, retatrutide, demonstrated significant reductions in A1C and weight in first Phase 3 trial for treatment of type 2 diabetes Eli Lilly and Company
FDA approves Lilly's Foundayo™ (orforglipron), the only GLP-1 pill for weight loss that can be taken any time of day without food or water restrictions - Eli Lilly and Company
FDA approves Lilly's Foundayo™ (orforglipron), the only GLP-1 pill for weight loss that can be taken any time of day without food or water restrictions Eli Lilly and Company
Lilly, Resilience to invest $750 million in US drug manufacturing expansion - Reuters
Lilly, Resilience to invest $750 million in US drug manufacturing expansion Reuters
Earnings Flash (LLY) Eli Lilly and Company Reports Q2 Revenue $22.97B, vs. FactSet Est of $20.69B - marketscreener.com
Earnings Flash (LLY) Eli Lilly and Company Reports Q2 Revenue $22.97B, vs. FactSet Est of $20.69B marketscreener.com
Lilly commits additional $4.5 billion across Indiana manufacturing sites, opens first dedicated genetic medicine facility - Eli Lilly and Company
Lilly commits additional $4.5 billion across Indiana manufacturing sites, opens first dedicated genetic medicine facility Eli Lilly and Company
Novo sues Lilly, claiming misleading ads in weight-loss drug battle - Reuters
Novo sues Lilly, claiming misleading ads in weight-loss drug battle Reuters
Lilly, with new data, to seek FDA approval of obesity drug retatrutide - BioPharma Dive
Lilly, with new data, to seek FDA approval of obesity drug retatrutide BioPharma Dive
Lilly reports first-quarter 2026 financial results, raises full year guidance, and highlights momentum of new medicines - Eli Lilly and Company
Lilly reports first-quarter 2026 financial results, raises full year guidance, and highlights momentum of new medicines Eli Lilly and Company
What’s Happening at Eli Lilly and Company (LLY)’s Pipeline? Early Signals Emerge - Yahoo Finance
What’s Happening at Eli Lilly and Company (LLY)’s Pipeline? Early Signals Emerge Yahoo Finance
Lilly's oral GLP-1 Foundayo (orforglipron) delivered superior A1C control and weight loss in three pivotal type 2 diabetes trials - Eli Lilly and Company
Lilly's oral GLP-1 Foundayo (orforglipron) delivered superior A1C control and weight loss in three pivotal type 2 diabetes trials Eli Lilly and Company
Breaking: World’s Largest Pharmaceutical Company, Eli Lilly, Acquires 5-MeO-DMT Developer AtaiBeckley for Up to $3.8 billion - Psychedelic Alpha
Breaking: World’s Largest Pharmaceutical Company, Eli Lilly, Acquires 5-MeO-DMT Developer AtaiBeckley for Up to $3.8 billion Psychedelic Alpha
Lilly to acquire Centessa Pharmaceuticals to advance treatments for sleep-wake disorders - Eli Lilly and Company
Lilly to acquire Centessa Pharmaceuticals to advance treatments for sleep-wake disorders Eli Lilly and Company
Eli Lilly nears deal to buy psychedelic drugmaker AtaiBeckley, Bloomberg News reports - Reuters
Eli Lilly nears deal to buy psychedelic drugmaker AtaiBeckley, Bloomberg News reports Reuters